Okay, so the user provided a question about why multidrug therapy is used in tuberculosis. The correct answer is probably related to preventing resistance. Let me start by recalling the core concept. TB treatment uses multiple drugs because using a single drug would lead to the development of resistant strains. The core principle here is pharmacodynamics and resistance prevention.

The patient is on INH, RIF, PZA, and EMB. The question is why combine them. The correct answer should be about overcoming resistance. I need to explain that each drug targets different aspects of the TB bacteria. For example, INH inhibits mycolic acid synthesis, RIF inhibits RNA synthesis, PZA is effective in acidic environments like macrophages, and EMB inhibits cell wall synthesis. Using multiple drugs reduces the chance of resistant mutants surviving.

Now, the wrong options. Let's say the options were about synergy, faster kill, fewer side effects, or something else. The incorrect options might be things like enhancing absorption, reducing side effects, or treating different species. I need to address each of those. For example, if an option says it's to reduce side effects, that's wrong because the drugs actually have more side effects combined. Another wrong option might be about treating co-infections, but TB treatment is specific for M. tuberculosis.

The clinical pearl here is that multidrug therapy is the cornerstone of TB treatment to prevent drug resistance. The mnemonic is RIFIN for the first-line drugs. Also, the standard initial regimen includes four drugs to attack the bacteria in different phases and environments.

**Core Concept**
Multidrug therapy in tuberculosis prevents the development of drug-resistant strains. *Mycobacterium tuberculosis* has a high mutation rate; monotherapy selects for resistant mutants, while multiple drugs with distinct mechanisms reduce this risk.

**Why the Correct Answer is Right**
Combining isoniazid, rifampicin, pyrazinamide, and ethambutol attacks *M. tuberculosis* through different pathways: isoniazid inhibits mycolic acid synthesis, rifampicin blocks RNA polymerase, pyrazinamide disrupts cell wall integrity in acidic environments (like phagosomes), and ethambutol inhibits arabinogalactan synthesis. This synergistic effect maximizes bacterial kill and minimizes the chance of resistance.

**Why Each Wrong Option is Incorrect**
**Option A:** "To enhance drug absorption" is incorrect. These drugs are absorbed well orally, and absorption isn’t the primary reason for combination therapy.
**Option B:** "To reduce hepatic toxicity" is false. Rifampicin and isoniazid actually increase hepatic toxicity risks.
**Option C:** "To treat co-infections" is irrelevant. The regimen targets *M. tuberculosis* specifically, not other pathogens.

**Clinical Pearl / High-Yield Fact**
Never use monotherapy for TB: resistance develops rapidly. The mnemonic **RIFIN** (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) helps recall first-line drugs. Multidrug therapy is the cornerstone of WHO-recommended treatment protocols.

**Correct Answer: C. To prevent the development of drug-resistant strains**

✓ Correct Answer: B. To delay development of resistance